Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
The JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor is the only approved drug for both newly diagnosed and previously treated myelofibrosis patients with anemia to address key disease manifestations including anemia, constitutional symptoms and enlarged spleen, according to GSKs press release
Cited 6/24/2026
The current GLP-1 drugs on the market, such as Wegovy and Zepbound, are dosed weekly, so a monthly option could be more convenient and attractive to patients
Complete side effect comparison table Here is the comprehensive comparison across all major side effect categories, summarizing the data covered throughout this guide
A systematic review with meta-analysis on 33 data sets with at least 10 years follow up, including a single center with 20 years of follow-up, found significant and sustained weight loss after surgery
US$ 25.94
US$ 26.24
US$ 28.94
US$ 20.31
US$ 25.50
US$ 28.36
US$ 28.24
US$ 27.15
US$ 22.42
